New NADPH Oxidase 2 Inhibitors Display Potent Activity against Oxidative Stress by Targeting p22<sup>phox</sup>-p47<sup>phox</sup> Interactions
Adriana V. Treuer,
Mario Faúndez,
Roberto Ebensperger,
Erwin Hovelmeyer,
Ariela Vergara-Jaque,
Yunier Perera-Sardiña,
Margarita Gutierrez,
Roberto Fuentealba,
Daniel R. González
Affiliations
Adriana V. Treuer
Department of Basic Biomedical Sciences, School of Health Sciences, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile
Mario Faúndez
Departamento de Farmacia, Escuela de Química y Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, Santiago 7820436, Chile
Roberto Ebensperger
Escuela de Química y Farmacia, Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago 7510157, Chile
Erwin Hovelmeyer
Center for Bioinformatics, Simulation and Modeling, Faculty of Engineering, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile
Ariela Vergara-Jaque
Center for Bioinformatics, Simulation and Modeling, Faculty of Engineering, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile
Yunier Perera-Sardiña
Department of Basic Biomedical Sciences, School of Health Sciences, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile
Margarita Gutierrez
Organic Synthesis Laboratory and Biological Activity (LSO-Act-Bio), Institute of Chemistry of Natural Resources, Universidad de Talca, Talca 3460000, Chile
Roberto Fuentealba
Escuela de Enfermería, Facultad de Salud, Universidad Santo Tomás, Talca 3460000, Chile
Daniel R. González
Department of Basic Biomedical Sciences, School of Health Sciences, Universidad de Talca, Avenida Lircay s/n, Talca 3460000, Chile
NADPH oxidase (NOX2) is responsible for reactive oxygen species (ROS) production in neutrophils and has been recognized as a key mediator in inflammatory and cardiovascular pathologies. Nevertheless, there is a lack of specific NOX2 pharmacological inhibitors. In medicinal chemistry, heterocyclic compounds are essential scaffolds for drug design, and among them, indole is a very versatile pharmacophore. We tested the hypothesis that indole heteroaryl-acrylonitrile derivatives may serve as NOX2 inhibitors by evaluating the capacity of 19 of these molecules to inhibit NOX2-derived ROS production in human neutrophils (HL-60 cells). Of these compounds, C6 and C14 exhibited concentration-dependent inhibition of NOX2 (IC50~1 µM). These molecules also reduced NOX2-derived oxidative stress in cardiomyocytes and prevented cardiac damage induced by ischemia-reperfusion. Compound C6 significantly reduced the membrane translocation of p47phox, a cytosolic subunit that is required for NOX2 activation. Molecular docking analyses of the binding modes of these molecules with p47phox indicated that C6 and C14 interact with specific residues in the inner part of the groove of p47phox, the binding cavity for p22phox. This combination of methods showed that novel indole heteroaryl acrylonitriles represent interesting lead compounds for developing specific and potent NOX2 inhibitors.